Total Payments
$243,344
2024 Payments
$33,567
Companies
26
Transactions
257
Medicare Patients
23,278
Medicare Billing
$25.1M
Payment Breakdown by Category
Consulting$175,949 (72.3%)
Other$36,268 (14.9%)
Travel$14,084 (5.8%)
Research$9,358 (3.8%)
Food & Beverage$7,570 (3.1%)
Education$76.00 (0.0%)
Gifts$38.80 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $175,949 | 73 | 72.3% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $18,455 | 6 | 7.6% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $16,313 | 4 | 6.7% |
| Travel and Lodging | $14,084 | 34 | 5.8% |
| Unspecified | $9,358 | 5 | 3.8% |
| Food and Beverage | $7,570 | 130 | 3.1% |
| Honoraria | $1,500 | 1 | 0.6% |
| Education | $76.00 | 2 | 0.0% |
| Gift | $38.80 | 2 | 0.0% |
Payments by Type
General
$233,986
252 transactions
Research
$9,358
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $49,830 | 32 | $0 (2024) |
| Bausch & Lomb Americas Inc. | $33,093 | 50 | $0 (2024) |
| Apellis Pharmaceuticals, Inc. | $29,979 | 17 | $0 (2024) |
| Bausch & Lomb, a division of Bausch Health US, LLC | $26,865 | 26 | $0 (2021) |
| Hoffmann-La Roche Limited | $21,756 | 5 | $0 (2023) |
| Regeneron Pharmaceuticals, Inc. | $21,471 | 31 | $0 (2024) |
| Allergan, Inc. | $16,699 | 23 | $0 (2021) |
| Valeant Pharmaceuticals North America LLC | $9,762 | 21 | $0 (2017) |
| Boehringer Ingelheim International GmbH | $8,872 | 4 | $0 (2024) |
| F. Hoffmann-La Roche AG | $8,599 | 6 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $33,567 | 50 | Regeneron Pharmaceuticals, Inc. ($11,370) |
| 2023 | $80,693 | 54 | Apellis Pharmaceuticals, Inc. ($22,396) |
| 2022 | $24,566 | 33 | Bausch & Lomb Americas Inc. ($9,296) |
| 2021 | $18,248 | 12 | Boehringer Ingelheim International GmbH ($6,500) |
| 2020 | $21,808 | 15 | Merck Sharp & Dohme Corporation ($6,500) |
| 2019 | $18,484 | 32 | Bausch & Lomb, a division of Bausch Health US, LLC ($5,921) |
| 2018 | $15,401 | 12 | Bausch & Lomb, a division of Bausch Health US, LLC ($9,721) |
| 2017 | $30,577 | 49 | Valeant Pharmaceuticals North America LLC ($9,762) |
All Payment Transactions
257 individual payment records from CMS Open Payments — Page 1 of 11
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $2,762.50 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/20/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $2,210.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/06/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $470.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 12/05/2024 | Boston Scientific Corporation | WaveWriter Alpha Prime 16 (Device) | Food and Beverage | In-kind items and services | $121.03 | General |
| Category: WaveWriter Alpha_NMD | ||||||
| 12/04/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $581.25 | General |
| 11/25/2024 | Bausch & Lomb Americas Inc. | SURGICAL MISC (Device) | Consulting Fee | Cash or cash equivalent | $750.00 | General |
| Category: Ophthalmology | ||||||
| 11/25/2024 | Bausch & Lomb Americas Inc. | SURGICAL MISC (Device) | Consulting Fee | Cash or cash equivalent | $500.00 | General |
| Category: Ophthalmology | ||||||
| 11/04/2024 | Bausch & Lomb Americas Inc. | Stellaris (Device) | Food and Beverage | In-kind items and services | $53.55 | General |
| Category: Ophthalmology | ||||||
| 10/19/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| Category: Ophthalmology | ||||||
| 10/19/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $77.04 | General |
| Category: Ophthalmology | ||||||
| 10/18/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | — | In-kind items and services | $1,828.00 | Research |
| Study: A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA • Category: OPHTHALMOLOGY | ||||||
| 10/10/2024 | Bausch & Lomb Americas Inc. | Stellaris (Device) | Food and Beverage | In-kind items and services | $32.43 | General |
| Category: Ophthalmology | ||||||
| 10/10/2024 | Bausch & Lomb Americas Inc. | Stellaris (Device) | Food and Beverage | In-kind items and services | $21.45 | General |
| Category: Ophthalmology | ||||||
| 10/03/2024 | Bausch & Lomb Americas Inc. | Stellaris (Device) | Food and Beverage | In-kind items and services | $26.60 | General |
| Category: Ophthalmology | ||||||
| 09/18/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $3,000.00 | General |
| 09/11/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $121.89 | General |
| Category: Ophthalmology | ||||||
| 09/05/2024 | Bausch & Lomb Americas Inc. | STELLARIS ELITE (Device) | Consulting Fee | Cash or cash equivalent | $1,000.00 | General |
| Category: Ophthalmology | ||||||
| 08/14/2024 | Bausch & Lomb Americas Inc. | XIPERE (Drug) | Food and Beverage | In-kind items and services | $31.84 | General |
| Category: Ophthalmology | ||||||
| 08/11/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $1,477.05 | General |
| 08/02/2024 | Alimera Sciences, Inc. | YUTIQ (Drug), ILUVIEN | Food and Beverage | In-kind items and services | $18.26 | General |
| Category: Treatment of chronic non-infectious uveitis affecting the posterior segment of the eye | ||||||
| 07/31/2024 | Bausch & Lomb Americas Inc. | Stellaris (Device) | Food and Beverage | In-kind items and services | $111.66 | General |
| Category: Ophthalmology | ||||||
| 07/22/2024 | Apellis Pharmaceuticals, Inc. | Syfovre (Drug) | Consulting Fee | Cash or cash equivalent | $4,887.00 | General |
| Category: Ophthalmology | ||||||
| 07/18/2024 | Apellis Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $80.88 | General |
| 07/05/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | — | In-kind items and services | $448.80 | Research |
| Study: A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA • Category: OPHTHALMOLOGY | ||||||
| 06/21/2024 | Bausch & Lomb Americas Inc. | — | Consulting Fee | Cash or cash equivalent | $1,500.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A PHASE III, DOUBLE-MASKED, MULTICENTER, RANDOMIZED, SHAM INJECTION-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF RANIBIZUMAB INJECTION IN SUBJECTS WITH CLINICALLY SIGNIFICANT MACULAR EDEMA WITH CENTER INVOLVEMENT SECONDARY TO DIABETES MELLITUS, A PHASE III, DOUBLE-MASKED, MULTICENTER, RANDOMIZED, SHAM INJECTION-CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF RANIBIZUMAB INJECTION IN SUBJECTS WITH CLINICALLY SIGNIFICANT MACULAR EDEMA WITH CENTER INVOLVEMENT SECONDARY TO DIABETES MELLITUS | F. Hoffmann-La Roche AG | $5,477 | 2 |
| A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | Regeneron Pharmaceuticals, Inc. | $2,277 | 2 |
| EYLEA CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $1,604 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 28 | 6,021 | 51,663 | $23.1M | $6.0M |
| 2022 | 24 | 5,727 | 35,277 | $24.3M | $6.3M |
| 2021 | 23 | 5,527 | 29,572 | $23.0M | $6.4M |
| 2020 | 22 | 6,003 | 29,311 | $22.3M | $6.4M |
Total Patients
23,278
Total Services
145,823
Medicare Billing
$25.1M
Procedure Codes
97
All Medicare Procedures & Services
97 procedure records from CMS Medicare Utilization — Page 1 of 4
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0178 | Injection, aflibercept, 1 mg | Office | 2023 | 226 | 2,696 | $6.6M | $1.9M | 28.3% |
| J2778 | Injection, ranibizumab, 0.1 mg | Office | 2023 | 343 | 6,889 | $6.2M | $1.3M | 21.0% |
| Q5128 | Injection, ranibizumab-eqrn (cimerli), biosimilar, 0.1 mg | Office | 2023 | 304 | 4,812 | $3.8M | $1.0M | 27.1% |
| J2777 | Injection, faricimab-svoa, 0.1 mg | Office | 2023 | 62 | 23,160 | $1.7M | $673,001 | 39.8% |
| 67028 | Injection of drug into eye | Office | 2023 | 674 | 3,303 | $1.6M | $334,884 | 20.4% |
| 92134 | Imaging of retina | Office | 2023 | 1,532 | 4,943 | $715,455 | $147,591 | 20.6% |
| 92012 | Established patient problem focused exam of visual system | Office | 2023 | 831 | 2,098 | $409,110 | $147,140 | 36.0% |
| 92014 | Established patient complete exam of visual system | Office | 2023 | 1,133 | 1,310 | $360,250 | $94,875 | 26.3% |
| J2781 | Injection, pegcetacoplan, intravitreal, 1 mg | Office | 2023 | 27 | 690 | $321,540 | $83,049 | 25.8% |
| J3490 | Unclassified drugs | Office | 2023 | 14 | 35 | $247,020 | $63,732 | 25.8% |
| J7312 | Injection, dexamethasone, intravitreal implant, 0.1 mg | Office | 2023 | 14 | 287 | $143,500 | $45,421 | 31.7% |
| 67042 | Removal of membrane of retina with removal of internal limiting membrane of retina | Facility | 2023 | 46 | 48 | $294,000 | $44,467 | 15.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 262 | 262 | $93,010 | $30,723 | 33.0% |
| 67113 | Complex repair of detached retina and drainage of eye fluid between lens and retina | Facility | 2023 | 20 | 21 | $155,925 | $22,603 | 14.5% |
| 67108 | Repair of detached retina with drainage and removal of eye fluid between lens and retina | Facility | 2023 | 14 | 15 | $102,525 | $14,602 | 14.2% |
| 67039 | Destruction of eye fluid (vitreous) between lens and retina using a laser | Facility | 2023 | 17 | 19 | $102,505 | $13,984 | 13.6% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Office | 2023 | 72 | 73 | $31,755 | $7,733 | 24.4% |
| J7999 | Compounded drug, not otherwise classified | Office | 2023 | 36 | 92 | $44,800 | $7,464 | 16.7% |
| 67515 | Injection of drug or substance into membrane covering eyeball | Office | 2023 | 46 | 110 | $36,160 | $4,243 | 11.7% |
| 92004 | New patient complete exam of visual system | Office | 2023 | 30 | 30 | $9,900 | $3,142 | 31.7% |
| 92201 | Extended exam of the back part of the eye with retinal drawing | Office | 2023 | 130 | 156 | $13,260 | $2,878 | 21.7% |
| 67145 | Photocoagulation treatment to prevent detachment of retina | Office | 2023 | 12 | 13 | $28,990 | $2,409 | 8.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 31 | 32 | $7,520 | $2,124 | 28.2% |
| 76512 | 2d ultrasound scan of eye tissue and structures | Office | 2023 | 41 | 49 | $10,535 | $1,815 | 17.2% |
| 92250 | Photography of the retina | Office | 2023 | 34 | 34 | $7,310 | $898.32 | 12.3% |
About Dr. Sunir Garg, M.D
Dr. Sunir Garg, M.D is a Ophthalmology healthcare provider based in Plymouth Meeting, Pennsylvania. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2005. The National Provider Identifier (NPI) number assigned to this provider is 1427056134.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Sunir Garg, M.D has received a total of $243,344 in payments from pharmaceutical and medical device companies, with $33,567 received in 2024. These payments were reported across 257 transactions from 26 companies. The most common payment nature is "Consulting Fee" ($175,949).
As a Medicare-enrolled provider, Garg has provided services to 23,278 Medicare beneficiaries, totaling 145,823 services with total Medicare billing of $25.1M. Data is available for 4 years (2020–2023), covering 97 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Other Specialties Retina Specialist, Retina Specialist
- Location Plymouth Meeting, PA
- Active Since 07/07/2005
- Last Updated 05/06/2019
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1427056134
Products in Payments
- Lucentis (Biological) $14,560
- EYLEA HD (Biological) $14,466
- STELLARIS PC (Device) $11,694
- STELLARIS (Device) $11,646
- SYFOVRE (Drug) $10,860
- Vabysmo (Drug) $9,660
- EYLEA (Biological) $7,475
- OZURDEX (Drug) $6,536
- XIPERE (Drug) $6,057
- Syfovre (Drug) $4,894
- RETISERT (Drug) $4,667
- LOTEMAX SM (Drug) $4,500
- PROLENSA (Drug) $3,000
- STELLARIS ELITE (Device) $2,875
- VISUDYNE (Drug) $2,250
- YUTIQ (Drug) $1,737
- SURGICAL MISC (Device) $1,250
- OPHTHALMIC INSTRUMENTS (Device) $937.50
- Stellaris (Device) $801.19
- VITESSE (Device) $539.08
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Plymouth Meeting
Carl Regillo, Md, MD
Ophthalmology — Payments: $909,778
Ophthalmology $909,778
Michael Klufas, M.d, M.D
Ophthalmology — Payments: $370,775
Ophthalmology $370,775
Allen Ho, Md, MD
Ophthalmology — Payments: $326,358
Ophthalmology $326,358
Dr. Ajay Kuriyan, M.d, M.D
Ophthalmology — Payments: $229,558
Ophthalmology $229,558
Omesh Gupta, Md, MD
Ophthalmology — Payments: $97,496
Ophthalmology $97,496
James Dunn, M.d, M.D
Ophthalmology — Payments: $53,152
Ophthalmology $53,152